The U.S. Nuclear Regulatory Commission (NRC) expects to make a final determination regarding the issuance of an operating license to SHINE Medical Technologies by October 2021, the company announced today.

“The review schedule established by the NRC for our application reflects the quality of our submission, our effective engagement with NRC staff and the diligence and hard work of the entire SHINE team,” SHINE CEO Greg Piefer said in a statement.

According to a release, SHINE’s application seeks the NRC’s approval to operate its transformational non-reactor technology at the Janesville, Wis., plant.

The biotech company’s application for a license to operate the medical isotope production facility in Janesville was accepted and docketed by the NRC last October.